BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $791,100 | -88.8% | 30,000 | -92.7% | 0.22% | -91.0% |
| Q2 2023 | $7,071,488 | -39.9% | 411,133 | -42.1% | 2.47% | -36.4% |
| Q1 2023 | $11,768,484 | +42.8% | 709,800 | +43.7% | 3.88% | +29.8% |
| Q4 2021 | $8,241,000 | -73.1% | 494,046 | -24.5% | 2.99% | -61.4% |
| Q3 2021 | $30,673,000 | -8.5% | 654,435 | +19.0% | 7.75% | -35.5% |
| Q2 2021 | $33,528,000 | -5.8% | 550,000 | -4.8% | 12.00% | -0.6% |
| Q1 2021 | $35,574,000 | +222.8% | 577,500 | +272.6% | 12.08% | +106.8% |
| Q4 2020 | $11,022,000 | – | 155,000 | – | 5.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |